Drug Trial Radar · NCT07862595
A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Nov 2, 2026
Primary completion
Jun 10, 2027
Study completion Jun 10, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new treatments for pain. While there are many approved treatments for pain, the treatments do not work well for everyone. People can also become addicted to certain pain medicines. Researchers designed a trial medicine called MK-6916 to treat pain. The goal of the trial is to learn if at least 1 dose of MK-6916 works better than placebo to lessen pain. A placebo looks like the trial medicine but has no trial medicine in it. Using a placebo helps researchers better understand the effects of the trial medicine.
Conditions
- Pain Management
Interventions
MK-6916Drug
120 mg or 70 mg oral tablet given every 12 hours (q12h) for 48 hours.
Hydrocodone/acetaminophen (HB/APAP)Drug
Hydrocodone 5 mg/acetaminophen 325 mg given as oral capsule every 6 hours (q6h) for 48 hours.
MK-6916 PlaceboDrug
Placebo oral table given every 6 hours (q6h) for 48 hours
Rescue MedicationDrug
Participants requesting rescue medication may receive protocol-specified rescue medication. Rescue treatment consists of open-label oxycodone immediate release (IR) oral tablet 5 mg given every 6 hours (q6h) (given in 5 mg increments for a maximum dose of 10 mg q6h). Participants should be encouraged to wait 1 hour after administration of the first dose of oxycodone 5 mg before administering a second dose. Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sum of the Pain Intensity Difference 0 to 48 Hours (SPID48)Time frame: Up to approximately 48 hours
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami ( Site 0718)
Miami, Florida · Recruiting
ForCare Clinical Research ( Site 0705)
Tampa, Florida · Recruiting
Atlanta Center for Medical Research ( Site 0708)
Atlanta, Georgia · Recruiting
Gateway Clinical Trails, Llc ( Site 0701)
O'Fallon, Illinois · Recruiting
Legent Orthopedic & Spine Hospital ( Site 0711)
Bellaire, Texas · Recruiting
Memorial Hermann Village ( Site 0704)
Houston, Texas · Recruiting
Futuro Clinical Trials ( Site 0703)
McAllen, Texas · Recruiting
Endeavor Clinical Trials PA ( Site 0700)
San Antonio, Texas · Recruiting
JBR Clinical Research ( Site 0702)
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.